Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

HSIC vs SNYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSIC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

HSIC Overall Winner 6-Pillar Tally: HSIC 4 – 2 SNYR Matrix Metrics: HSIC 8 – 2 SNYR

As of Nov 20, 2026, Henry Schein Inc (HSIC) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HSIC carries a Unified Composite Score of 50.9/100 (HOLD) at $83.52 (13.9x Forward P/E, 5.8% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin).

  • Technical & Structure Timing Caution: HSIC is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.5); meanwhile SNYR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HSIC vs SNYR
HSIC NASDAQ Head-to-Head Winner
Henry Schein Inc
Wholesale-Medical, Dental & Hospital Equipment & Supplies
$83.52
-1.51% 1D
Market Cap $9.4B
TTM Revenue $13.7B
Forward P/E 13.9x
Beta / 30D Vol 0.55β · 40% Vol
Unified Composite Score
50.9 / 100 HOLD
Tech 50.0 Fund 53.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.7%) with fading momentum, RSI 45
RSI-14: 44.5 · SMA20: $85.68 · SMA50: $85.50
SNYR NASDAQ
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14

6-Pillar Scorecard Institutional Category Breakdown (HSIC 4 – 2 SNYR)

Columns: Metric · HSIC · SNYR
1. Valuation Multiples SNYR
Forward P/E 13.9x 0.6x
Trailing P/E 23.2x 0.6x
PEG Ratio 1.67x N/M
EV / Revenue 1.0x 0.1x
2. Growth & Scale HSIC
Revenue Growth (YoY) +4.0% -32.8%
Earnings Growth (YoY) +26.2% -90.6%
TTM Revenue (USD) $13.7B $28M
Market Cap $9.4B $4.1M
3. Profitability & Quality HSIC
Gross Margin 31.6% 65.4%
Operating Margin 5.8% -10.3%
Net Profit Margin 3.1% -57.0%
Return on Equity (ROE) 9.2% -361.1%
4. Balance Sheet & Cash Flow HSIC
Cash Generation (TTM) $500M -$3.8M
Cash Flow Margin 3.6% -13.7%
Net Cash / Leverage $3.71B Net Debt (1.23x D/E) -361.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HSIC
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 29.4% (8th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity 25.8% of Rev ($3.54B) 75.7% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Distribution Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HSIC (8) vs SNYR (2)
Institutional Metric HSIC SNYR Criterion Row Edge
Market Capitalization
Scale
$9.4B $4.1M Larger Scale HSIC
Trailing P/E Ratio
Valuation
23.2x 0.6x Lower Multiple SNYR
Forward P/E Ratio
Valuation
13.9x 0.6x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
+4.0% -32.8% Higher Growth HSIC
Operating Margin (TTM)
Profitability
5.8% -10.3% Higher Margin HSIC
Net Profit Margin
Profitability
3.1% -57.0% Higher Margin HSIC
Return on Equity (ROE)
Capital Efficiency
9.2% -361.1% Higher ROE HSIC
52-Week Range Position
Momentum
63% ($69–$92) 1% ($0–$3) Stronger Trend HSIC
Beta / 30D Volatility
Risk Regime
0.55β · 40% Vol -0.86β · 868% Vol Lower Realized Risk HSIC
Unified Institutional Score
Composite Signal
50.9 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite HSIC
Trailing 12M Revenue (USD)
Operating Scale
$13.7B $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
31.6% 65.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.67x PEG · 1.0x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$500M ($3.71B Net Debt (1.23x D/E)) -$3.8M (-361.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HSIC +11.58 pp
HSIC: -4.7% · SNYR: -16.28%
3M Horizon HSIC +62.98 pp
HSIC: +6.34% · SNYR: -56.64%
6M Horizon HSIC +109.5 pp
HSIC: +16.3% · SNYR: -93.2%
1Y Horizon HSIC +116.58 pp
HSIC: +20.45% · SNYR: -96.13%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HSIC Revenue SNYR Revenue HSIC Op. Margin SNYR Op. Margin Margin Leader
FY2018 $9.42B $30M 6.4% -14.5% HSIC
FY2019 $9.99B $30M 7.2% -27.1% HSIC
FY2020 $10.1B N/A 5.3% N/A HSIC
FY2021 $12.4B N/A 6.9% N/A HSIC
FY2022 $12.7B N/A 5.9% N/A HSIC
FY2023 $12.3B $40M 5.0% 25.3% SNYR
FY2024 $12.7B $30M 4.9% 16.7% SNYR
FY2025 $13.2B $30M 5.0% -27.8% HSIC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HSIC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 29.4%
IV Percentile 8th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact HSIC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HSIC Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $9.4B market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment 25.8% of Rev ($3.54B)
90D Engineering Disclosures 0 Published
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ HSIC vs SNYR Key Questions & Quantitative Answers

As of Nov 20, 2026, Henry Schein Inc (HSIC) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HSIC carries a Unified Composite Score of 50.9/100 (HOLD) at $83.52 (13.9x Forward P/E, 5.8% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin). Technical & Structure Timing Caution: HSIC is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.5); meanwhile SNYR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSIC leads the Growth & Scale pillar: HSIC posts +4.0% YoY revenue growth and +26.2% YoY earnings growth on $13.7B TTM revenue (31.6% gross margin, 5.8% operating margin), compared with SNYR at -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), HSIC cumulative revenue shifted +39.9% while SNYR shifted +0.0%. In operating R&D and SG&A reinvestment, HSIC deploys 25.8% of Rev ($3.54B) (0 90-day corporate R&D disclosures) versus 75.7% of Rev ($21M) (0 disclosures) for SNYR.

SNYR screens cheaper on headline valuation multiples. HSIC trades at 13.9x Forward P/E, 23.2x Trailing P/E, 1.67x PEG, and 1.0x EV/Revenue (3.6% FCF margin), whereas SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSIC (9.2% ROE) versus SNYR (-361.1% ROE) capital efficiency.

In options market volatility and institutional positioning, HSIC carries 29.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 40% Vol realized risk). By comparison, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.